CD34+ selected cells in clinical transplantation.
The CD34 antigen is expressed by early hematopoietic stem cells and progenitors and is detected on the surface of approximately 1% of bone marrow mononuclear cells [1-3]. Several monoclonal antibody-based methods have been developed to isolate these cells from clinical samples of bone marrow or peripheral blood based on their expression of this antigen, utilizing either biotin-avidin affinity, panning or immunomagnetic beads. Roughly 50% of CD34+ cells, with 20-90% purity, are recovered from clinical samples using these methods. Several clinical trials have demonstrated hematopoietic recovery using CD34+ selected cells to support high dose therapy. CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. This paper reviews the current methods for purification of CD34+ cells from clinical samples and discusses potential uses of these cells in transplantation.
Collins
R H
RH
Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246.
D015703:Antigens, CD / Q000378:metabolism*; D018952:Antigens, CD34; D016465:Bone Marrow Purging; D002469:Cell Separation / Q000379:methods; D015316:Genetic Therapy; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D008212:Lymphocyte Depletion; D013601:T-Lymphocytes / Q000276:immunology
D015703:Antigens, CD; D018952:Antigens, CD34